EMD 273063 antibody, human

Known as: Hu 14.18/IL - 2 Fusion Protein, hu14.18-interleukin-2 fusion protein, EMD 273063 
A recombinant protein consisting of the hu14.18 monoclonal antibody fused to the cytokine interleukin-2 (IL2) with potential antineoplastic activity… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2000-2014
012320002014

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Immunotherapy targeting disialoganglioside GD2 emerges as an important treatment option for neuroblastoma, a pediatric malignancy… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2012
2012
Phase I testing of the hu14.18-IL2 immunocytokine in melanoma patients showed immune activation, reversible toxicities, and a… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2011
2011
The huKS-IL2 immunocytokine (IC) consists of IL2 fused to a mAb against EpCAM, while the hu14.18-IL2 IC recognizes the GD2… (More)
  • figure 1
  • figure 3
  • figure 4
  • figure 5
  • figure 7
Is this relevant?
2010
2010
Response to immunocytokine (IC) therapy is dependent on natural killer cells in murine neuroblastoma (NBL) models. Furthermore… (More)
  • table 3
  • table 4
  • table 5
  • table 7
  • table 6
Is this relevant?
2009
2009
To explore the biological activity of EMD 273063 (hu14.18-IL2), a humanized anti-GD2 monoclonal antibody fused to interleukin-2… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2008
2008
Immunocytokines (IC), consisting of tumor-specific monoclonal antibodies fused to the immunostimulatory cytokine interleukin 2… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2006
2006
PURPOSE Evaluate the clinical safety, toxicity, immune activation/modulation, and maximal tolerated dose of hu14.18-IL2 (EMD… (More)
  • table 2
  • table 3
  • table 4
  • table 5
  • table 6
Is this relevant?
2004
2004
PURPOSE To evaluate the safety, toxicity, in vivo immunologic activation, and maximum-tolerated dose (MTD) of EMD 273063 (hu14.18… (More)
Is this relevant?
2004
2004
Established s.c. NXS2 murine neuroblastoma tumors exhibited transient resolution after suboptimal therapy using the hu14.18-IL2… (More)
Is this relevant?
2003
2003
We evaluated recurrent NXS2 neuroblastoma tumors that developed following NK- or T-cell–mediated immunotherapy in tumor-bearing… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 4
Is this relevant?